Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 171

1.

The Global Meningococcal Initiative meeting on prevention of meningococcal disease worldwide: epidemiology, surveillance, hypervirulent strains, antibiotic resistance and high-risk populations.

Acevedo R, Bai X, Borrow R, Caugant DA, Carlos J, Ceyhan M, Christensen H, Climent Y, De Wals P, Dinleyici EC, Echaniz-Aviles G, Hakawi A, Kamiya H, Karachaliou A, Lucidarme J, Meiring S, Mironov K, Sáfadi MAP, Shao Z, Smith V, Steffen R, Stenmark B, Taha MK, Trotter C, Vázquez JA, Zhu B.

Expert Rev Vaccines. 2018 Dec 10. doi: 10.1080/14760584.2019.1557520. [Epub ahead of print] No abstract available.

PMID:
30526162
2.

A Longitudinal Epidemiology Study of Meningococcal Carriage in Students 13 to 25 Years Old in Quebec.

Gilca R, De Wals P, Nolan SM, Kitchin N, Eiden JJ, Jiang Q, Jones CH, Jansen KU, Anderson AS, Pedneault L.

mSphere. 2018 Dec 5;3(6). pii: e00427-18. doi: 10.1128/mSphere.00427-18.

3.

Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine Against Invasive Disease Caused by Serotype 3 in Children: A Systematic Review and Meta-Analysis of Observational Studies.

Sings HL, De Wals P, Gessner BD, Isturiz R, Laferriere C, McLaughlin JM, Pelton S, Schmitt HJ, Suaya JA, Jodar L.

Clin Infect Dis. 2018 Oct 23. doi: 10.1093/cid/ciy920. [Epub ahead of print]

PMID:
30357326
4.

Limited impact of pneumococcal vaccines on invasive pneumococcal disease in Nunavik (Quebec).

LeMeur JB, Lefebvre B, Proulx JF, De Wals P.

Can J Public Health. 2018 Oct 19. doi: 10.17269/s41997-018-0138-2. [Epub ahead of print]

PMID:
30341482
5.

Overview of knowledge, attitudes, beliefs, vaccine hesitancy and vaccine acceptance among mothers of infants in Quebec, Canada.

Dubé È, Farrands A, Lemaitre T, Boulianne N, Sauvageau C, Boucher FD, Tapiero B, Quach C, Ouakki M, Gosselin V, Gagnon D, De Wals P, Petit G, Jacques MC, Gagneur A.

Hum Vaccin Immunother. 2018 Aug 10:1-8. doi: 10.1080/21645515.2018.1509647. [Epub ahead of print]

PMID:
30095325
6.

Commentary on paradoxical observations pertaining to the impact of the 13-valent pneumococcal conjugate vaccine on serotype 3 Streptococcus pneumoniae infections in children.

De Wals P.

Vaccine. 2018 Sep 5;36(37):5495-5496. doi: 10.1016/j.vaccine.2018.07.069. Epub 2018 Aug 1. No abstract available.

PMID:
30077481
7.

Prevalence of middle ear abnormalities from otitis media in relation with pneumococcal vaccine use in the Inuit population of Nunavik, province of Quebec, Canada.

Le Meur JB, Ayukawa H, Proulx JF, De Wals P.

Vaccine. 2018 Aug 16;36(34):5180-5186. doi: 10.1016/j.vaccine.2018.07.008. Epub 2018 Jul 17.

8.

A postpartum vaccination promotion intervention using motivational interviewing techniques improves short-term vaccine coverage: PromoVac study.

Gagneur A, Lemaître T, Gosselin V, Farrands A, Carrier N, Petit G, Valiquette L, De Wals P.

BMC Public Health. 2018 Jun 28;18(1):811. doi: 10.1186/s12889-018-5724-y.

10.

Individual and School Correlates of Adolescent Leisure Time Physical Activity in Quebec, Canada.

Massougbodji J, Lebel A, De Wals P.

Int J Environ Res Public Health. 2018 Feb 27;15(3). pii: E412. doi: 10.3390/ijerph15030412.

11.

Incidence of invasive pneumococcal disease before and during an era of use of three different pneumococcal conjugate vaccines in Quebec.

De Wals P, Lefebvre B, Deceuninck G, Longtin J.

Vaccine. 2018 Jan 8;36(3):421-426. doi: 10.1016/j.vaccine.2017.11.054. Epub 2017 Dec 7.

PMID:
29224962
12.

Hospitalisation for lower respiratory tract infection in children in the province of Quebec, Canada, before and during the pneumococcal conjugate vaccine era.

Anderson G, Deceuninck G, Zhou Z, Boucher FD, Bonnier Viger Y, Gilca R, De Wals P.

Epidemiol Infect. 2017 Oct;145(13):2770-2776. doi: 10.1017/S0950268817001510. Epub 2017 Aug 14.

PMID:
28803551
13.

The Quebec experience in promoting healthy lifestyles and preventing obesity: how can we do better?

Le Bodo Y, Blouin C, Dumas N, De Wals P, Laguë J.

Obes Rev. 2017 Sep;18(9):967-986. doi: 10.1111/obr.12559. Epub 2017 May 30. Review.

PMID:
28557192
14.

Policy making for vaccine use as a driver of vaccine innovation and development in the developed world.

Seib K, Pollard AJ, de Wals P, Andrews RM, Zhou F, Hatchett RJ, Pickering LK, Orenstein WA.

Vaccine. 2017 Mar 7;35(10):1380-1389. doi: 10.1016/j.vaccine.2016.10.080. Review.

PMID:
28253995
15.

Forecasting Trends in Invasive Pneumococcal Disease among Elderly Adults in Quebec.

Zhou Z, Deceuninck G, Lefebvre B, De Wals P.

Can J Infect Dis Med Microbiol. 2017;2017:4347206. doi: 10.1155/2017/4347206. Epub 2017 Jan 26.

16.

Impact of an Immunization Campaign to Control an Increased Incidence of Serogroup B Meningococcal Disease in One Region of Quebec, Canada.

De Wals P, Deceuninck G, Lefebvre B, Tsang R, Law D, De Serres G, Gilca V, Gilca R, Boulianne N.

Clin Infect Dis. 2017 May 1;64(9):1263-1267. doi: 10.1093/cid/cix154.

PMID:
28207068
17.

Cost-effectiveness Comparison of Monovalent C Versus Quadrivalent ACWY Meningococcal Conjugate Vaccination in Canada.

De Wals P, Zhou Z.

Pediatr Infect Dis J. 2017 Jul;36(7):e203-e207. doi: 10.1097/INF.0000000000001512.

PMID:
28027288
18.

The Global Meningococcal Initiative: global epidemiology, the impact of vaccines on meningococcal disease and the importance of herd protection.

Borrow R, Alarcón P, Carlos J, Caugant DA, Christensen H, Debbag R, De Wals P, Echániz-Aviles G, Findlow J, Head C, Holt D, Kamiya H, Saha SK, Sidorenko S, Taha MK, Trotter C, Vázquez Moreno JA, von Gottberg A, Sáfadi MA; Global Meningococcal Initiative.

Expert Rev Vaccines. 2017 Apr;16(4):313-328. doi: 10.1080/14760584.2017.1258308. Epub 2016 Nov 22. Review.

PMID:
27820969
19.

Effectiveness of three pneumococcal conjugate vaccines to prevent invasive pneumococcal disease in Quebec, Canada.

De Wals P, Deceuninck G, De Serres G.

Vaccine. 2016 Apr 19;34(18):2053-4. doi: 10.1016/j.vaccine.2015.06.104. No abstract available.

PMID:
27021043
20.

Predictors of hospitalization for lower respiratory tract infection in children aged <2 years in the province of Quebec, Canada.

Zhou Z, Gilca R, Deceuninck G, Boucher FD, Charest H, DE Wals P.

Epidemiol Infect. 2016 Apr;144(5):1035-44. doi: 10.1017/S0950268815002204. Epub 2015 Sep 18.

PMID:
26381086
21.

Comparison of Phenotypic and Genotypic Approaches to Capsule Typing of Neisseria meningitidis by Use of Invasive and Carriage Isolate Collections.

Jones CH, Mohamed N, Rojas E, Andrew L, Hoyos J, Hawkins JC, McNeil LK, Jiang Q, Mayer LW, Wang X, Gilca R, De Wals P, Pedneault L, Eiden J, Jansen KU, Anderson AS.

J Clin Microbiol. 2016 Jan;54(1):25-34. doi: 10.1128/JCM.01447-15. Epub 2015 Aug 26.

23.

Effectiveness of three pneumococcal conjugate vaccines to prevent invasive pneumococcal disease in Quebec, Canada.

Deceuninck G, De Serres G, Boulianne N, Lefebvre B, De Wals P.

Vaccine. 2015 May 28;33(23):2684-9. doi: 10.1016/j.vaccine.2015.04.005. Epub 2015 Apr 15.

PMID:
25887086
24.

Risk of narcolepsy associated with inactivated adjuvanted (AS03) A/H1N1 (2009) pandemic influenza vaccine in Quebec.

Montplaisir J, Petit D, Quinn MJ, Ouakki M, Deceuninck G, Desautels A, Mignot E, De Wals P.

PLoS One. 2014 Sep 29;9(9):e108489. doi: 10.1371/journal.pone.0108489. eCollection 2014.

25.

Uptake of pneumococcal vaccines in the Nordic region of Nunavik, province of Quebec, Canada.

Cléophat JE, Le Meur JB, Proulx JF, De Wals P.

Can J Public Health. 2014 May 30;105(4):e268-72.

PMID:
25166129
26.

Pediatric Pleural Empyema in the Province of Quebec: Analysis of a 10-Fold Increase Between 1990 and 2007.

Deceuninck G, Quach C, Panagopoulos M, Thibeault R, Côté-Boileau T, Tapiéro B, Coïc L, De Wals P, Ovetchkine P.

J Pediatric Infect Dis Soc. 2014 Jun;3(2):119-26. doi: 10.1093/jpids/pit075. Epub 2013 Dec 6.

PMID:
26625364
27.

Reviews examining sugar-sweetened beverages and body weight: correlates of their quality and conclusions.

Massougbodji J, Le Bodo Y, Fratu R, De Wals P.

Am J Clin Nutr. 2014 May;99(5):1096-104. doi: 10.3945/ajcn.113.063776. Epub 2014 Feb 26. Review.

PMID:
24572563
28.

Respiratory infection and otitis media visits in relation to pneumococcal conjugate vaccine use in Saskatchewan.

Khuc NH, Tan B, Tuchscherer R, Rawson NS, De Wals P.

Can J Infect Dis Med Microbiol. 2013 Winter;24(4):179-84.

29.

Impact of 2+1 pneumococcal conjugate vaccine program in the province of Quebec, Canada.

De Wals P, Lefebvre B, Markowski F, Deceuninck G, Defay F, Douville-Fradet M, Landry M.

Vaccine. 2014 Mar 14;32(13):1501-6. doi: 10.1016/j.vaccine.2013.11.028. Epub 2014 Jan 31.

PMID:
24486346
30.

Impact of pneumococcal vaccines use on invasive pneumococcal disease in Nunavik (Quebec) from 1997 to 2010.

Le Meur JB, Lefebvre B, Proulx JF, Déry S, Pépin J, De Wals P.

Int J Circumpolar Health. 2014 Jan 17;73:22691. doi: 10.3402/ijch.v73.22691. eCollection 2014.

31.

Burden of rotavirus disease: A population-based study in Eastern Townships, Quebec.

Bernard S, Valiquette L, De Wals P, Nault V, Babakissa C, Cyr C, Boileau TC, Gagneur A.

Can J Infect Dis Med Microbiol. 2013 Fall;24(3):138-42.

32.

Evaluation of serogroup C and ACWY meningococcal vaccine programs: projected impact on disease burden according to a stochastic two-strain dynamic model.

Vickers DM, Anonychuk AM, De Wals P, Demarteau N, Bauch CT.

Vaccine. 2015 Jan 1;33(1):268-75. doi: 10.1016/j.vaccine.2013.09.034. Epub 2013 Oct 6.

33.

Evaluation of several approaches to immunize parents of neonates against B. pertussis.

Frère J, De Wals P, Ovetchkine P, Coïc L, Audibert F, Tapiero B.

Vaccine. 2013 Dec 9;31(51):6087-91. doi: 10.1016/j.vaccine.2013.09.043. Epub 2013 Oct 5.

PMID:
24099874
34.

International collaboration to assess the risk of Guillain Barré Syndrome following Influenza A (H1N1) 2009 monovalent vaccines.

Dodd CN, Romio SA, Black S, Vellozzi C, Andrews N, Sturkenboom M, Zuber P, Hua W, Bonhoeffer J, Buttery J, Crawford N, Deceuninck G, de Vries C, De Wals P, Gutierrez-Gimeno MV, Heijbel H, Hughes H, Hur K, Hviid A, Kelman J, Kilpi T, Chuang SK, Macartney K, Rett M, Lopez-Callada VR, Salmon D, Gimenez-Sanchez F, Sanz N, Silverman B, Storsaeter J, Thirugnanam U, van der Maas N, Yih K, Zhang T, Izurieta H; Global H1N1 GBS Consortium.

Vaccine. 2013 Sep 13;31(40):4448-58. doi: 10.1016/j.vaccine.2013.06.032. Epub 2013 Jun 14.

PMID:
23770307
35.

Long-term persistence of immunity after vaccination of pre-adolescents with low doses of a recombinant hepatitis B vaccine.

Gilca V, De Serres G, Boulianne N, Murphy D, Ouakki M, De Wals P, Trudeau G, Massé R, Dionne M.

Hum Vaccin Immunother. 2013 Aug;9(8):1685-90. doi: 10.4161/hv.25015. Epub 2013 Jun 6.

36.

Factors associated with HPV vaccination among adult women in Quebec.

Kiely M, Sauvageau C, Dubé E, Deceuninck G, De Wals P.

Hum Vaccin Immunother. 2013 Jul;9(7):1421-4. doi: 10.4161/hv.24603. Epub 2013 Apr 9.

37.

The changing epidemiology of meningococcal disease in Quebec, Canada, 1991-2011: potential implications of emergence of new strains.

Gilca R, Deceuninck G, Lefebvre B, Tsang R, Amini R, Gilca V, Douville-Fradet M, Markowski F, De Wals P.

PLoS One. 2012;7(11):e50659. doi: 10.1371/journal.pone.0050659. Epub 2012 Nov 29.

38.

Antibody persistence and the effect of a booster dose given 5, 10 or 15 years after vaccinating preadolescents with a recombinant hepatitis B vaccine.

Gilca V, De Serres G, Boulianne N, Murphy D, De Wals P, Ouakki M, Trudeau G, Massé R, Dionne M.

Vaccine. 2013 Jan 7;31(3):448-51. doi: 10.1016/j.vaccine.2012.11.037. Epub 2012 Dec 1.

PMID:
23206974
39.

The burden of childhood pneumonia in the developed world: a review of the literature.

Madhi SA, De Wals P, Grijalva CG, Grimwood K, Grossman R, Ishiwada N, Lee PI, Nascimento-Carvalho C, Nohynek H, O'Brien KL, Vergison A, Wolter J.

Pediatr Infect Dis J. 2013 Mar;32(3):e119-27. doi: 10.1097/INF.0b013e3182784b26. Review.

PMID:
23099423
40.

Invasive pneumococcal diseases in birth cohorts vaccinated with PCV-7 and/or PHiD-CV in the province of Quebec, Canada.

De Wals P, Lefebvre B, Defay F, Deceuninck G, Boulianne N.

Vaccine. 2012 Oct 5;30(45):6416-20. doi: 10.1016/j.vaccine.2012.08.017. Epub 2012 Aug 21.

PMID:
22921290
41.

Risk of Guillain-Barré syndrome following H1N1 influenza vaccination in Quebec.

De Wals P, Deceuninck G, Toth E, Boulianne N, Brunet D, Boucher RM, Landry M, De Serres G.

JAMA. 2012 Jul 11;308(2):175-81. doi: 10.1001/jama.2012.7342.

PMID:
22782419
42.

Invasive serogroup B Neisseria meningitidis in Quebec, Canada, 2003 to 2010: persistence of the ST-269 clone since it first emerged in 2003.

Zhou J, Lefebvre B, Deng S, Gilca R, Deceuninck G, Law DK, De Wals P, Tsang RS.

J Clin Microbiol. 2012 May;50(5):1545-51. doi: 10.1128/JCM.06835-11. Epub 2012 Feb 15.

43.

[Human papilloma virus: knowledge, beliefs and behavior of Quebec women].

Kiely M, Sauvageau C, Dubé E, Deceuninck G, De Wals P.

Can J Public Health. 2011 Jul-Aug;102(4):303-7. French.

PMID:
21913589
44.

Effectiveness of serogroup C meningococcal conjugate vaccine: a 7-year follow-up in Quebec, Canada.

De Wals P, Deceuninck G, Lefebvre B, Boulianne N, De Serres G.

Pediatr Infect Dis J. 2011 Jul;30(7):566-9. doi: 10.1097/INF.0b013e31820e8638.

PMID:
21326136
45.

Burden of acute otitis media on Canadian families.

Dubé E, De Wals P, Gilca V, Boulianne N, Ouakki M, Lavoie F, Bradet R.

Can Fam Physician. 2011 Jan;57(1):60-5.

46.

Optimizing the acceptability, effectiveness and costs of immunization programs: the Quebec experience.

De Wals P.

Expert Rev Vaccines. 2011 Jan;10(1):55-62. doi: 10.1586/erv.10.151. Review.

PMID:
21162621
47.

Quality of life of children and their caregivers during an AOM episode: development and use of a telephone questionnaire.

Dubé E, De Wals P, Ouakki M.

Health Qual Life Outcomes. 2010 Jul 26;8:75. doi: 10.1186/1477-7525-8-75.

48.

Uptake of pneumococcal conjugate vaccine: methodological issues in measurement and impact of publicly funded programs.

De Wals P, Boulianne N, Sévin E, Ouakki M, Deceuninck G, Guay M.

Can J Public Health. 2009 Nov-Dec;100(6):413-6.

PMID:
20209732
49.

Modeling the impact of one- and two-dose varicella vaccination on the epidemiology of varicella and zoster.

Brisson M, Melkonyan G, Drolet M, De Serres G, Thibeault R, De Wals P.

Vaccine. 2010 Apr 26;28(19):3385-97. doi: 10.1016/j.vaccine.2010.02.079. Epub 2010 Mar 1.

PMID:
20199763
50.

Effectiveness of pneumococcal conjugate vaccine using a 2+1 infant schedule in Quebec, Canada.

Deceuninck G, De Wals P, Boulianne N, De Serres G.

Pediatr Infect Dis J. 2010 Jun;29(6):546-9. doi: 10.1097/INF.0b013e3181cffa2a.

PMID:
20125062

Supplemental Content

Loading ...
Support Center